The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.
 
Masatoshi Kudo
Honoraria - Ajinomoto; Bayer; Eisai; Kaken Pharmaceutical; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; MSD; Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kowa; MSD; Otsuka; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Ho Yeong Lim
No Relationships to Disclose
 
Do Young Kim
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - Astellas Pharma; AstraZeneca Japan; Baxter; Bayer Yakuhin; Celgene; Daiichi Sankyo; Dainippon Sumitomo Pharma; EA Pharma; Fujifilm; Lilly Japan; Merck Serono; Nippon Chemiphar; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Baxter (Inst); Bayer Yakuhin (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shizuoka Industry (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly Japan; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb; Lilly Japan; NanoCarrier
Research Funding - AstraZeneca (Inst); Baxter (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Hisashi Hidaka
No Relationships to Disclose
 
Jong-Eun Yeon
No Relationships to Disclose
 
Eishiro Mizukoshi
No Relationships to Disclose
 
Manabu Morimoto
Honoraria - Bayer; Dainippon Sumitomo Pharma; Eisai; Nippon Kayaku
Research Funding - Bayer (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Shionogi (Inst); Yakult Pharmaceutical (Inst)
 
Myung Ah Lee
No Relationships to Disclose
 
Kohichiroh Yasui
No Relationships to Disclose
 
Yasunori Kawaguchi
No Relationships to Disclose
 
Jeong Heo
Consulting or Advisory Role - Abbvie
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Roche
 
Sojiro Morita
No Relationships to Disclose
 
Tae-You Kim
No Relationships to Disclose
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Kazuhiro Katayama
Speakers' Bureau - Ajinomoto; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Otsuka
Research Funding - ASKA Pharmaceutical (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Kowa (Inst)
 
Takeshi Aramaki
No Relationships to Disclose
 
Won-Young Tak
Consulting or Advisory Role - Abbvie; Gilead Sciences
Research Funding - Samil Pharmaceutical